☆ 4.2 Article

Clinical Application of Intravitreal Aflibercept Injection for Diabetic Macular Edema Comparing Two Loading Regimens

MEDICINA-LITHUANIA (2023)

Related references

Note: Only part of the references are listed.

Review Ophthalmology

Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods

Osama A. Sorour et al.

Summary: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment has improved the outcomes for patients with diabetic macular edema (DME), but persistent DME (pDME) may occur despite intensive treatment. Criteria for defining treatment-resistant eyes with pDME have not been standardized. Treatment options for pDME include switching anti-VEGF agents, using corticosteroids and/or antioxidant drugs in addition to anti-VEGF therapy, and vitrectomy. Multimodal imaging may help predict treatment responsiveness. This literature review explores the defining criteria, incidence, baseline biomarkers, and available treatment options for pDME.

SURVEY OF OPHTHALMOLOGY (2023)

Add to Collection

Article Ophthalmology

Intravitreal dexamethasone insert in diabetic macular edema super-refractory to anti-vascular endothelial growth factor therapy

Carl S. Wilkins et al.

Summary: The study findings indicate that intravitreal dexamethasone insert is effective in eyes with super-refractory DME, resulting in excellent anatomical improvement on SD-OCT as well as modest visual improvement. The injection burden was reduced in patients who would otherwise receive years of monthly treatments.

EUROPEAN JOURNAL OF OPHTHALMOLOGY (2022)

Add to Collection

Article Medicine, Research & Experimental

Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial

Justus G. Garweg et al.

Summary: The study compares two flexible regimens of intravitreal aflibercept (IVT-AFL) with a fixed dosing regimen in patients with diabetic macular edema. The results show no significant difference in best-corrected visual acuity changes compared to fixed dosing, but the T&E regimen has the lowest treatment burden.

ADVANCES IN THERAPY (2022)

Add to Collection

Article Ophthalmology

Fluctuations in macular thickness in patients with diabetic macular oedema treated with anti-vascular endothelial growth factor agents

Victoria Y. Wang et al.

Summary: This study evaluated retinal thickness fluctuations in diabetic macular oedema patients treated with anti-VEGF injections and found that larger fluctuations were associated with poorer visual outcomes. Predictors of fluctuation included baseline thickness, injection type, laser treatment, and diabetic retinopathy stage.

EYE (2022)

Add to Collection

Review Pharmacology & Pharmacy

Safety and Outcomes of Intravitreal Aflibercept in Diabetic Macular Edema - A Systematic Review

Ana Maria Dascalu et al.

Summary: This article systematically reviews the outcomes and safety of intravitreal aflibercept therapy in diabetic macular edema. The results show significant improvement in visual acuity and a good safety profile. Further randomized studies are needed to determine the optimal treatment frequency.

CURRENT PHARMACEUTICAL DESIGN (2022)

Add to Collection

Article Ophthalmology

Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes

Masahiko Sugimoto et al.

Summary: This study reports the safety and effectiveness of intravitreal aflibercept (IVT-AFL) for diabetic macular edema (DME) in the real-world clinical practice setting in Japan. The results show that routine administration of IVT-AFL for DME was not associated with new safety concerns, and best-corrected visual acuity outcomes were maintained over 24 months in the real-world setting.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema

Chirag D. Jhaveri et al.

Summary: The relative efficacy of administering aflibercept monotherapy compared with bevacizumab followed by aflibercept if there is insufficient improvement in eyes with diabetic macular edema is uncertain.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Ophthalmology

Treat-and-extend therapy with aflibercept for diabetic macular edema: a prospective clinical trial

Takao Hirano et al.

Summary: The study findings suggest that a treat-and-extend (T&E) regimen using aflibercept with the longest treatment interval set to 16 weeks is a feasible and rational strategy for the treatment of diabetic macular edema (DME) over a period of 1 year. Although the improvement in best-corrected visual acuity (BCVA) may be slightly less compared to frequent treatment, the T&E aflibercept regimen shows promising results in terms of central subfield macular thickness (CST) improvement. Participants who demonstrated an early response to initial treatment showed greater vision improvement at 1 year, indicating the potential effectiveness of this treatment approach.

JAPANESE JOURNAL OF OPHTHALMOLOGY (2021)

Add to Collection

Review Ophthalmology

Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045 Systematic Review and Meta-analysis

Zhen Ling Teo et al.

Summary: The translated paragraphs provide updated estimates on the global prevalence and number of people with diabetic retinopathy (DR) through 2045. The burden of DR is expected to increase disproportionately in countries in the Middle East and North Africa and the Western Pacific by 2045. Certain ethnic groups such as Hispanics and Middle Easterners with diabetes are more likely to have DR compared to Asians.

OPHTHALMOLOGY (2021)

Add to Collection

Article Ophthalmology

Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial Setting

Matthew R. Starr et al.

Summary: This study found that large fluctuations in CST may indicate worse VA outcomes in patients with DME at the 2-year endpoint.

AMERICAN JOURNAL OF OPHTHALMOLOGY (2021)

Add to Collection

Article Ophthalmology

One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders

Ali Salimi et al.

Summary: This study investigated the anatomical and functional changes associated with Aflibercept treatment in Bevacizumab nonresponders with chronic DME in a Canadian setting. The results highlighted the efficacy of Aflibercept as an alternative therapeutic option for DME recalcitrant to Bevacizumab, with potential additional benefit to those with worse vision, greater CST, and better glycemic control at baseline.

INDIAN JOURNAL OF OPHTHALMOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Efficacy of Conversion to Aflibercept for Diabetic Macular Edema Previously Refractory to Bevacizumab or Ranibizumab: A Meta-analysis of High-Quality Nonrandomized Studies

Kang Xiao et al.

ANNALS OF PHARMACOTHERAPY (2020)

Add to Collection

Article Ophthalmology

Impact of Systemic Dipeptidyl Peptidase-4 Inhibitor Use in Diabetic Macular Edema

Ehsan Rahimy et al.

OPHTHALMIC SURGERY LASERS & IMAGING RETINA (2020)

Add to Collection

Article Multidisciplinary Sciences

Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema

Yu Cheol Kim et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Article Ophthalmology

Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept - A Retrospective Cohort Study

Christoph Kern et al.

CLINICAL OPHTHALMOLOGY (2020)

Add to Collection

Article Endocrinology & Metabolism

Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition

Pouya Saeedi et al.

DIABETES RESEARCH AND CLINICAL PRACTICE (2019)

Add to Collection

Article Ophthalmology

Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment A Secondary Analysis of a Randomized Clinical Trial

Neil M. Bressler et al.

JAMA OPHTHALMOLOGY (2018)

Add to Collection

Article Ophthalmology

Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T

Neil M. Bressler et al.

AMERICAN JOURNAL OF OPHTHALMOLOGY (2018)

Add to Collection

Review Ophthalmology

Current management of diabetic tractional retinal detachments

Michael W. Stewart et al.

INDIAN JOURNAL OF OPHTHALMOLOGY (2018)

Add to Collection

Review Ophthalmology

Aflibercept in the treatment of diabetic macular edema: a review and consensus paper

Teresio Avitabile et al.

EUROPEAN JOURNAL OF OPHTHALMOLOGY (2017)

Add to Collection

Article Ophthalmology

Intravitreal Aflibercept for Diabetic Macular Edema 148-Week Results from the VISTA and VIVID Studies

Jeffrey S. Heier et al.

OPHTHALMOLOGY (2016)

Add to Collection

Article Ophthalmology

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial

John A. Wells et al.

OPHTHALMOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

John A. Wells et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Ophthalmology

Intravitreal Aflibercept for Diabetic Macular Edema 100-Week Results From the VISTA and VIVID Studies

David M. Brown et al.

OPHTHALMOLOGY (2015)

Add to Collection

Article Ophthalmology

Intravitreal Aflibercept for Diabetic Macular Edema

Jean-Francois Korobelnik et al.

OPHTHALMOLOGY (2014)

Add to Collection

Article Ophthalmology

Proposed Lexicon for Anatomic Landmarks in Normal Posterior Segment Spectral-Domain Optical Coherence Tomography

Giovanni Staurenghi et al.

OPHTHALMOLOGY (2014)

Add to Collection

Article Cell Biology

Expression of VEGF-A, Otx Homeobox and p53 Family Genes in Proliferative Vitreoretinopathy

Claudio Azzolini et al.

MEDIATORS OF INFLAMMATION (2013)

Add to Collection

Article Ophthalmology

The DA VINCI Study: Phase 2 Primary Results of VEGF Trap-Eye in Patients with Diabetic Macular Edema

Diana V. Do et al.

OPHTHALMOLOGY (2011)

Add to Collection

Article Ophthalmology

Diagnosis of Macular Edema

Jose Cunha-Vaz et al.

OPHTHALMOLOGICA (2010)

Add to Collection

Article Endocrinology & Metabolism

The pathobiology of diabetic complications - A unifying mechanism

M Brownlee

DIABETES (2005)

Add to Collection

Review Ophthalmology

Visual impairment and blindness in Europe and their prevention

I Kocur et al.

BRITISH JOURNAL OF OPHTHALMOLOGY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.